Aims: This study aimed to investigate the influence of tightened regulations on new psychoactive substances in patients with disorders related to these drugs in Japan.
Methods: We used a biennial nationwide survey on drug-related psychiatric disorders to examine why individuals who had previously used new psychoactive substances as their primary drug (the drug that had the greatest impact on their psychiatric symptoms) had switched to other drugs, how they had used drugs in the last 12 months and what type of drugs they were now using. We compared the clinical features of these individuals with patients who mainly used new psychoactive substances and had used these drugs at least once in the last 12 months.
Results: A total of 2262 people were included, and 399 had used new psychoactive substances. Of those, 71 people had switched to another drug as primary drug, mostly stimulant drugs (35.2%), hypnotics and anxiolytics (15.5%), and cannabis (14.1%) and used these drugs during the previous 12 months. The majority, 53.3%, had switched "because new psychoactive substances were no longer available." In total, 25 people mainly used new psychoactive substances. The group that had changed drugs had more experience of using methamphetamine and were more likely to have abused other drugs before using new psychoactive substances. They had often switched to illegal or prescription drugs after regulations had been tightened.
Conclusion: The number of patients abusing new psychoactive substances decreased after drug regulations were tightened, but new psychoactive substances-related problems still exist. It is therefore not enough to tighten regulations. Drug dependence treatment and recovery support are also needed.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292308 | PMC |
| http://dx.doi.org/10.1002/npr2.12035 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
STNGS: a deep scaffold learning-driven generation and screening framework for discovering potential novel psychoactive substances.
Brief Bioinform
November 2024
School of Science, China Pharmaceutical University, Nanjing 211198, China.
The supervision of novel psychoactive substances (NPSs) is a global problem, and the regulation of NPSs was heavily relied on identifying structural matches in established NPSs databases. However, violators could circumvent legal oversight by altering the side chain structure of recognized NPSs and the existing methods cannot overcome the inaccuracy and lag of supervision. In this study, we propose a scaffold and transformer-based NPS generation and Screening (STNGS) framework to systematically identify and evaluate potential NPSs.
View Article and Find Full Text PDFThe synthetic cannabinoid 5F-ADB induced developmental toxicity in Daphnia magna through disrupting the oxidative stress system and the nervous conduction system.
Chemosphere
December 2024
School of Engineering, China Pharmaceutical University, Nanjing 210009, China. Electronic address:
Methyl 2-{[1-(5-fluoropentyl)-1H-indazole-3-carbonyl]amino}-3,3-dimethylbutanoate (5F-ADB), which is classified as an illicit drug in China and most European countries, is susceptible to abuse. The abuse of 5F-ADB must avoid entering the water environment. However, the aquatic toxic effects of 5F-ADB remain unclear.
View Article and Find Full Text PDFTramadol as a fentanyl adulterant: Prevalence and management in a ToxIC Fentalog study prospective cohort.
Am J Emerg Med
December 2024
Icahn School of Medicine at Mount Sinai, Center for Research on Emerging Substances, Poisoning, Overdose, and New Discoveries (RESPOND), NYC Health + Hospitals/Elmhurst, New York, NY, USA.
Background: Tramadol is an adulterant of illicit opioids. As it is a serotonin-norepinephrine reuptake inhibitor as well as a μ-opioid agonist, tramadol adulteration may worsen overdose signs and symptoms or affect the amount of naloxone patients receive.
Methods: This is a multicenter, prospective cohort of adult patients with suspected opioid overdoses who presented to one of eight United States emergency departments and were included in the Toxicology Investigators Consortium's Fentalog Study.
Health-Promoting Behaviors in Male Patients with Opioid Use Disorder: An Exploratory Study.
J Psychoactive Drugs
December 2024
National Drug Dependence Treatment Centre, All India Institute of Medical Sciences, New Delhi, India.
Health-promoting lifestyle and behaviors play a crucial role in the prognosis of an illness as well as in healing. With the significant global burden of unhealthy lifestyle choices, their impact on individuals with substance use disorders can be particularly burdensome, hampering overall well-being. This study assesses health-promoting lifestyle and behavior and dietary habits among treatment-seeking male patients with opioid use disorders.
View Article and Find Full Text PDFThe Effect of Modafinil Treatment on Cravings in Methamphetamine Use Disorder.
J Psychoactive Drugs
December 2024
Department of Psychiatry, Sakarya University Faculty of Medicine, Sakarya, Turkey.
There is a need for treatments that can reduce cravings in methamphetamine use disorder (MUD), which is trending upwards worldwide. The aim of this study was to evaluate the effect of modafinil treatment on substance craving in patients with MUD. The study included 100 patients with MUD who were being treated in an inpatient detoxification center.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!